Coherus Biosciences shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $4 to $1.5.
Portfolio Pulse from Benzinga Newsdesk
Coherus Biosciences shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $4 to $1.5.
August 16, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS downgraded Coherus Biosciences from Buy to Neutral and lowered its price target from $4 to $1.5, causing the stock to trade lower.
The downgrade from UBS and the significant reduction in the price target are likely to negatively impact investor sentiment and lead to a short-term decline in Coherus Biosciences' stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100